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The differential diagnosis and etiologic classification of the two main forms of thrombotic 
microangiopathy (TMA) —thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic 
uraemic syndrome (aHUS)— remain challenging1. The terms TTP and HUS are used to describe the 
clinical presentation of these diseases. HUS has prominent renal involvement, whereas neurological 
manifestations are common in TTP. The distinction is not always reliable; neurologic complications 
can be present in patients with aHUS and renal failure not requiring dialysis can be present in 
patients affected by TTP. 
 aHUS is characterised by hyperactivation of the alternative complement pathway2,3, whilst TTP is 
characterised by the severe deficiency of the von Willebrand factor (VWF) cleaving protease 
ADAMTS134. The prevalence of severe ADAMTS13 deficiency (i.e. activity below 10%) in TTP is 
high in patients with idiopathic disease and none or minimal renal involvement. However in a 
proportion of patients with idiopathic TTP and minor renal involvement at acute disease 
presentation, ADAMTS13 activity may be only slightly reduced or even normal. The 
pathophysiological mechanisms in these patients are unknown. In order to clarify the etiology in a 
patient (27 year old female) with acute TTP and normal ADAMTS13 activity, we investigated the 
complement system-, ADAMTS13-, and VWF-related biochemical properties5,6 at acute phase and 
during remission. Concentration of the complement system components C3, C4 and factor H were 
measured by radial immunodiffusion using commercial methods. C3 and C4 levels were measured 
by C3 and C4 NOR Partigen (Siemens, Marburg, Germany). Complement system activity was 
evaluated by ELISA (Wieslab complement assay, EuroDiagnostica, Malmö, Sweden). The wells of 
microtitre strips were coated with specific activators of the classical, alternative or mannose-binding 
lectin pathway, and the serum was diluted in a buffer containing specific blockers in order to ensure 
that only one pathway was activated during incubation. The wells were then washed and membrane 
attack complex (C5b-9) was detected. Anti-factor H antibodies were assayed by an enzyme-linked 
immunosorbent assay (ELISA) that used purified factor H for capture and anti-human 
immunoglobulin G (IgG), A (IgA) and M (IgM) for detection 7. 
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We performed exome sequencing to identify potentially causal mutations. Three first-degree 
relatives of the patient, including the patient’s mother and her two sons, were also studied. The 
study was approved by the institutional review board of the Fondazione IRCCS Ca’ Granda – 
Ospedale Maggiore Policlinico. All participants signed informed consent. 
Our patient presented to her local hospital with fever, respiratory tract infection, abdominal pain, 
and headache. She had no past medical history and didn’t take any drugs. Laboratory investigations 
revealed thrombocytopenia (platelet counts: 14 x 109/L; normal values [nv]: 150-450 x 109/L) and 
microangiopathic hemolytic anemia (hemoglobin: 8.9 g/dL; nv: 11.5-16.0 g/dL) with negative 
Coombs test and evidence of schistocytes in peripheral blood smear and reduced haptoglobin levels 
(34 mg/dl n.v. 45-164). Total and indirect bilirubin (43.6 and 38.2 µmol/l; n.v.< 20 µmol/l and n.v.< 
7 µmol/l) and lactate dehydrogenase (4559 U/l; n.v.: 160-320 U/l) were increased. Serum creatinine 
was slightly increased (117 µmol/L; nv: 53-106 µmol/L), but the patient did not have renal failure 
according to the RIFLE (Risk, Injury, Failure, Loss, ESRD) criteria. Creatinine levels returned to 
normal levels (89 µmol/L) within 48 hours. A diagnosis of TTP was made and plasma exchange 
(PEX) commenced. Remission was achieved after 7 plasma exchange procedures. The patient 
initiated regular follow-up and remained relapse-free seven years after the episode. She had two 
pregnancies without complications. Consumption of VWF multimers of large and intermediate size 
was observed. The finding of reduced ULVWF ratio in acute phase could suggest a TTP-like TMA, 
despite normal ADAMTS13 levels, with the proposed mechanism: the excess of ULVWF (possibly 
due to endothelial cells activation and ULVWF release) overwhelmed ADAMTS13 cleaving 
activity, with VWF-mediated platelet aggregation and ULVWF consumption in the thrombi. 
Recently Cataland et al reported that patients with aHUS did not showed mid- to large- sized  VWF 
multimer in acute phase 8. 
Low C3 and C4 levels as well as low activity of the classical and alternative complement pathways 
may reflect a consumption of complement factors due to activation. This explanation is supported 
by the observation that during remission complement levels normalized. A selective activation of 
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alternative pathway is typical of aHUS, but a degree of classical pathway activation is described 9. 
Not only complement parameters, but also all the other measurements were normal during 
remission (Table 1). 
We sequenced the entire protein coding are of the genome by Illumina HiSeq 2000. In the exome of 
the patient, we identified 25068 SNVs and 209 open reading frame indels. A total of 12 SNVs in 6 
genes were found. We focused on complement factor and complement regulation genes (CFH, CFI, 
CD46, CFB, THBD and C3 genes). Sequencing identified 9 single nucleotide variants (SNVs; 6 
missense or splice-site SNVs and 3 additional coding synonymous SNVs reported in Supplemental 
Table 2 ). We did not detect short insertions or deletions (indels) in these genes. Neither C3, CFB, 
CFHR3, CFHR4, nor THBD had functional variants. Of all variants found in the protein-coding 
area of thrombotic-microangiopathy-associated genes, one was novel: i.e. not present in dbSNP139 
(URL: http://www.ncbi.nlm.nih.gov/SNP/http://www.1000genomes.org/faq/how-do-i-cite-1000-
genomes-project) or in 1000 Genomes (URL ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/). 
This novel variant was a heterozygous splice-site SNV of CD46 (c.475+1G>A), encoding the 
complement protein MCP. Notably, we did not find the variant in 90 Italian controls by PCR and 
Sanger sequencing. Association of CD46 splice-site variants with aHUS have been reported 
previously10,11. The CD46 variant is predicted by NetGene2 and Spliceport to abolish the natural 
donor splice site of exon 4, creating an alternative splice-site into the exon 4. The activation of the 
new splice-site is predicted to result in the deletion of 21 nucleotides 
(c.631_652delTAAGCCCCCAATATGTGAAA), determining the lack of 6 aminoacids 
(p.G152_C157del). These analyses suggest that the variant may be causally implicated in the TMA 
of our patient. In order to support this hypothesis, we screened for the variant in the family 
members of the patient, and also made measurements related to the complement activation. Genetic 
studies on first degree relatives have potential psychologic and financial implications for them, but 
the identification of carriers of mutations may allow adequate follow-up of at-risk subjects, 
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particularly during triggering events such as infections and pregnancy. In fact is  known that aHUS 
penetrance is incomplete. 
To this end, we studied the circulating CD46 mRNA by reverse transcription PCR (RT-PCR) and 
found that both sons of the patient had the c.475+1G>A variant (in heterozygous form), whereas her 
mother did not. Meanwhile, complement system measurements showed activation of the alternative 
complement pathway in the younger of the two sons (Son 2) and no alteration of complement 
activation in the older son (Son 1), nor in the mother of the patient. Real time PCR and Sanger 
sequencing of the CD46 mRNA spanning exons 3-6 confirmed the presence of the altered CD46 
transcript bearing the deletion of 21 nucleotides in the patient and in both sons. Expression of MCP 
was analysed on granulocytes from the patient and a control subject using a FACSAria 
cytofluorometer (BD Bioscences) and showed a 50% reduction of this protein. 
The differential diagnosis of TMAs is challenging. TTP is accompanied by severe deficiency of 
ADAMTS13 activity, whilst aHUS is characterized by complement system abnormalities due to 
genetic mutations. Severe ADAMTS13 deficiency has been described in a proportion of patients 
with a clinical diagnosis of aHUS previously,12 suggesting that these disorders could overlap not 
only for their clinical characteristics, but also for their pathophysiological mechanisms.  
In this patient with an isolated episode of TMA and minimal renal impairment, a detailed 
phenotypic characterization followed by exome-wide genetic analysis identified a novel CD46 
mutation as a likely cause for the TMA. Interestingly, the patient did not show signs of prominent 
renal involvement and was diagnosed with TTP. The novel finding of our report is that a patient 
with TMA clinically resembling TTP and minor renal involvement may carry a rare, disruptive 
genetic variant of complement regulator gene, such as CD46. 
This case of TMA at presentation did not meet a clear-cut criteria for diagnosis of  either TTP or 
aHUS, because the clinical presentation is TTP-like. However, non-deficient ADAMTS13 activity 
at presentation and in remission, evidence of complement activation at presentation and the finding 
of a mutation of CD46 collectively support the hypothesis that the most appropriate diagnosis 
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would be that of a complement-mediated TMA/aHUS rather than a diagnosis of TTP. This case 
report emphasizes the need for a new classification of different types of TMA based not only on 
clinical presentation, but also on disease mechanism and molecular evaluation. A new classification 
of TMA is important because the therapeutic approach to TTP and aHUS is evolving and more 
etiology-based. New tailored therapies are being introduced and used in combination with PEX. 
These include anti-CD20 antibodies13, inhibitors of VWF-platelet interactions14 and “terminal 
complement” pathway inhibitors15 like eculizumab. As the therapeutic approach to different forms 
of TMA diverges, it is becoming more important to establish the underlying etiology. This paper 
confirms the utility of the analysis of both the ADAMTS13 activity and complement evaluation in 
patients with acute TMA.    
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Table 1. ADAMTS13-, VWF- and complement system-related plasmatic measurements at acute 
disease and remission in the patient.  
Parameter Normal values Acute disease Remission 
ADAMTS13 activity, % 46-160 47 100 
ADAMTS13 antigen, % 40-155 71 86 
Anti-ADAMTS13 antibodiesa Absent Absent Absent 
VWF antigen, % 55-165 194 150 
ULVWF ratio 0.85-1.21 0.50 1.01 
Classical complement pathway 
activity, % 69-129 56 79 
Alternative complement pathway 
activity, % 30-113 24 60 
Mannose binding lectin complement 
pathway activity, % 0-125 45 74 
C3, % 70-130 69 114 
C4, % 70-130 58 77 
FH antigen, % 66-122 62 94 
Anti-FH antibodies, Unit/mL Less than 5.20 1.55 0.09 
 
VWF, von Willebrand factor; ULVWF, ultra-large forms of von Willebrand factor; C3, complement system 
component 3; C4, complement system component C4, FH, complement system factor H. 
aAnti-ADAMTS13 antibodies were screened by western blotting. 
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Figure 1. Reverse transcription PCR analysis of the CD46 transcripts in the patient and her 
family. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The figure shows the results of southern blotting of CD46 cDNA (upper left), the family tree (upper 
right), , and the Sanger sequencing traces (bottom). Family tree: I, II, and III indicate the 
generations. Sanger traces: A, mother who carried wild-type CD46 alleles; B, patient; C, first son; 
D, the second son; B, C, and D carried the CD46 c.475+1G>A heterozygote variant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
